United Kingdom witnessing widespread expansion of 32Co's Sleep Centre network, aiming to combat escalating sleep disorder predicament
The UK is set to witness a significant development in the treatment of obstructive sleep apnoea (OSA) and problematic snoring, with the expansion of Aerox Sleep Centres by London-based healthtech company 32Co. This summer, specialist centres will open in major UK cities, including London, Manchester, Edinburgh, and Bristol, with more to follow nationwide [1].
The Aerox Sleep Centres aim to make treatment for OSA and snoring widely accessible, addressing a current gap where patient access is limited. The centres utilize a platform to upskill dentists in these treatments, enabling more local and specialist intervention [1].
32Co focuses on using custom mandibular advancement splints (MADs), a dental device known to help manage sleep-related breathing disorders, guided by clinical leadership from experts like Professor Ama Johal, a world-renowned specialist in dental sleep medicine [1].
The integration of these centres with 32Co’s existing network brings orthodontic and specialist dental care close to most of the UK population, facilitating a collaborative approach between general clinicians and dental sleep specialists to improve outcomes [1][2].
By creating a marketplace for custom-made treatment devices and a network of localised centres, 32Co is filling a market gap and potentially reducing the burden on conventional sleep clinics and NHS services, which often have long wait times for OSA diagnosis and treatment [1].
The expansion of Aerox Sleep Centres is supported by significant funding (£7 million raised), indicating strong investor confidence in this healthcare vertical and its potential impact in the UK market [1].
MADs have been shown to have higher adherence rates than Continuous Positive Airway Pressure (CPAP) machines, with patients typically using MADs for 6.5 hours per night vs CPAP 5.2 hours per night. The CPAP machine, the industry standard treatment method against sleep apnoea, is often found uncomfortable, claustrophobic, and difficult to travel with, leading to treatment discontinuation [1].
Pre-pilot trials of Aerox Sleep Centres and MADs have helped hundreds of patients improve their sleep. For instance, Michael, 58, from London, reported waking up less tired and grumpier without his sleep device, while John, 69, from Manchester, stated that he would sleep downstairs with the dog if his sleep device broke [1].
The key impacts of this expansion include improved patient access, an innovative treatment approach, integration with existing healthcare, market and healthcare impact, and financial and strategic backing [1][2].
However, it's important to note that the Aerox Sleep Centres will focus on treating patients with mild to moderate obstructive sleep apnoea (OSA) and problematic snoring [1]. While snoring is linked to various serious medical conditions, including hypertension, heart failure, coronary artery disease, pulmonary hypertension, atrial fibrillation, and stroke, it's crucial to seek professional help if experiencing persistent or severe symptoms [1].
For many, the unobtrusive nature of MADs makes them an attractive option. Helen, 64, from London, believes many people would benefit from MADs, as they are less intrusive compared to other treatment methods [1]. However, it's essential to consult a healthcare professional before making any decisions regarding treatment.
The expansion of Aerox Sleep Centres represents a significant step forward in addressing the widespread issue of OSA and problematic snoring in the UK. With its patient-centred approach and innovative technology, 32Co is poised to make a positive impact on the lives of many [1][2].
